Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.

Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS.

Oncology. 2011;80(5-6):373-81. doi: 10.1159/000329040. Epub 2011 Aug 3.

2.

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL.

J Clin Oncol. 2011 Oct 10;29(29):3892-9. doi: 10.1200/JCO.2011.36.0636. Epub 2011 Sep 12.

3.

Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging.

Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC.

Ann Hepatol. 2013 Nov-Dec;12(6):915-25.

4.

V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.

Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS.

Cancer. 2011 Jun 1;117(11):2478-88. doi: 10.1002/cncr.25791. Epub 2010 Dec 14.

5.

Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju088. doi: 10.1093/jnci/dju088.

6.

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.

Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group..

PLoS Med. 2016 Apr 26;13(4):e1002006. doi: 10.1371/journal.pmed.1002006. eCollection 2016 Apr.

7.

Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy.

Nanashima A, Sumida Y, Abo T, Shindou H, Fukuoka H, Takeshita H, Hidaka S, Tanaka K, Sawai T, Yasutake T, Nagayasu T, Omagari K, Mine M.

J Gastroenterol. 2006 Mar;41(3):250-6.

PMID:
16699859
8.

A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.

Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI, Lee SD.

J Hepatol. 2010 Jul;53(1):108-17. doi: 10.1016/j.jhep.2010.01.038. Epub 2010 Mar 31.

PMID:
20451283
9.

A prognostic index for patients within the intermediate stage of hepatocellular carcinoma.

Di Costanzo GG, Signoriello S, Tortora R, Gallo C.

Eur J Gastroenterol Hepatol. 2016 May;28(5):592-8. doi: 10.1097/MEG.0000000000000562.

PMID:
26974431
10.

A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma.

Zhang BH, Wang XH, Yue HY, Ling CQ.

J Cancer Res Clin Oncol. 2010 Jun;136(6):821-7. doi: 10.1007/s00432-009-0722-1. Epub 2009 Nov 15.

PMID:
19916022
12.

The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.

Gómez-Rodríguez R, Romero-Gutiérrez M, Artaza-Varasa T, González-Frutos C, Ciampi-Dopazo JJ, de-la-Cruz-Pérez G, Sánchez-Ruano JJ.

Rev Esp Enferm Dig. 2012 Jun;104(6):298-304. English, Spanish.

13.

Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?

Morace C, Cucunato M, Bellerone R, De Caro G, Crinò S, Fortiguerra A, Spadaro F, Zirilli A, Alibrandi A, Consolo P, Luigiano C, Resta ML, Ferraù O, Spadaro A.

Eur J Intern Med. 2012 Sep;23(6):e157-61. doi: 10.1016/j.ejim.2012.04.014. Epub 2012 May 24.

PMID:
22863442
14.

Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma.

Shao YY, Liu TH, Lee YH, Hsu CH, Cheng AL.

J Gastroenterol Hepatol. 2016 Jul;31(7):1336-41. doi: 10.1111/jgh.13312.

PMID:
26860846
15.

Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.

Hayashi M, Shimizu T, Hirokawa F, Inoue Y, Komeda K, Asakuma M, Miyamoto Y, Takeshita A, Shibayama Y, Tanigawa N.

Am Surg. 2011 May;77(5):572-8.

PMID:
21679590
16.

A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.

Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW.

J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.

PMID:
25690672
17.

Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma.

Karabulut S, Duranyıldız D, Tas F, Gezer U, Akyüz F, Serilmez M, Ozgür E, Yasasever CT, Vatansever S, Aykan NF.

Tumour Biol. 2014 Mar;35(3):2729-39. doi: 10.1007/s13277-013-1360-4. Epub 2013 Nov 23.

PMID:
24272080
18.

Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection.

Huang S, Huang GQ, Zhu GQ, Liu WY, You J, Shi KQ, Wang XB, Che HY, Chen GL, Fang JF, Zhou Y, Zhou MT, Chen YP, Braddock M, Zheng MH.

PLoS One. 2015 Jun 9;10(6):e0129000. doi: 10.1371/journal.pone.0129000. eCollection 2015.

19.

Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T.

Hepatology. 2004 Dec;40(6):1396-405.

PMID:
15565571
20.

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB.

J Hepatol. 2014 Feb;60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. Epub 2013 Sep 14.

Supplemental Content

Support Center